BofA is Bullish on CRISPR Therapeutics AG (CRSP)
On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 1,296 | $67,962 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.96 | 1,508 | $49,703.68 | 1,508 | 2025-04-03 | Filing | |
| $57.03 | 20,000 | $1,140,600.00 | 22,000 | 2025-08-06 | Filing | |
| $52.03 | 960,983 | $49,999,945.49 | 1,730,179 | 2025-07-16 | Filing | |
| $52.03 | 22,319 | $1,161,257.57 | 238,897 | 2025-07-16 | Filing | |
| $52.03 | 6,510 | $338,715.30 | 69,687 | 2025-07-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $60.19 | 34,972 | $2,104,964.68 | 6,767 | 2026-01-22 | Filing | |
| $60.23 | 60,000 | $3,613,800.00 | 134,201 | 2026-01-22 | Filing | |
| $52.10 | 8,567 | $446,340.70 | 194,201 | 2026-01-20 | Filing | |
| $51.61 | 21,433 | $1,106,157.13 | 202,768 | 2026-01-20 | Filing | |
| $60.21 | 5,763 | $347,009.82 | 6,767 | 2026-01-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,524,144 | $132,366,111 | 0.02% | |
| 2. | 2,268,394 | $118,954,581 | 0% | |
| 3. | 1,958,111 | $102,683,341 | 0.06% | |
| 4. | Imc-chicago, LlcCALL | 479,900 | $25,165,956 | 0.01% |
| 5. | 198,000 | $10,383,120 | 0% |
News See All
Growth Stock Portfolio: 12 Stock Picks By Cathie Wood
After a severe 2022 decline, Cathie Wood's flagship innovation fund witnessed a dramatic comeback through 2025, climbing 87.1% in the year ending in September 2025 and tripling over three years, according...
Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP)
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74.
Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here.
12 Best Genomics Stocks to Invest In
Companies that study DNA to improve people's lives are known as genomics stocks.
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update
CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in.
12 Best Emerging Technology Stocks to Invest In
On December 24, Kevin Simpson of Capital Wealth Planning joined 'Closing Bell' on CNBC to talk about AI tailwinds and the diverging tech picture.
What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio.
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now.
Cathie Wood's Stock Portfolio: Top 10 Stocks to Buy
Catherine “Cathie” Wood has been leading the investment management firm ARK Investment Management LLC ("ARK Invest") as its Founder, CEO, and CIO for nearly 15 years.
Hedge Fund Resource Center Billionaire Hedge Funds
